Bookmark and Share

Ming T Tan
 

Ming T Tan Ph.D.

Academic Title: Adjunct Professor
Primary Appointment: Epidemiology & Public Health
mttan@som.umaryland.edu
Location: MSTF, 261
Phone: (410) 706-8506
Fax: (410) 706-8548

Personal History:

Dr. Tan is professor of Epidemiology and Preventive Medicine and Head of the Division of Biostatistics of the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC). He has been on the faculty since 2002. He is a member of the center's Experimental Therapeutics Program. He was previously a senior member (faculty) at St. Jude Children's Research Hospital Cancer Center and biostatistics director of St Jude's Developmental Therapeutics for Solid Malignancies Program (1997-2002), assistant and associate professor of Biostatistics and Epidemiology at The Cleveland Clinic Foundation (1990-1997). He received his Ph.D. in statistics from Purdue University, Indiana.

Dr. Tan has extensive collaborative research experience in the design, conduct and analysis of clinical trials (in both multi-center and single institutional settings), laboratory investigations and epidemiological research. He is also the Principal Investigator (PI) of the NCI R01 grant on the Design & Analysis of Preclinical Combination to develop innovative methods to optimally design and efficiently analyze pre-clinical drug combination therapies in cancer by integrating concepts in modern statistical and number-theoretic methods and pharmacology. He was PI of the NCI RO3 grant on "Design and Analysis of Cancer Epidemiology Studies" and PI on NIH R01 grant on "Clinical Trial Design and Interim Analysis." Dr. Tan has served multiple Data and Safety Monitoring Boards for clinical trials.

He is a member of FDA Advisory Committee and of multiple NIH study sections (such as Clinical Oncology and Epidemiology of Cancer), review and site visit panels (such as that for SPOREs and P30). He is a Fellow of the American Statistical Association and an elected Member of the International Statistical Institute. Dr. Tan is Associate Editor of Statistics in Medicine and Drug Design, Development and Therapy. He has also served on the editorial board of Biometrics.

EDUCATION

1978-1982: B.S. Wuhan University, Wuhan, China , Numerical Analysis (Computational Mathematics)
1983-1986: M.S. Joint Statistics Program of Central China Normal University and Wuhan University, Wuhan, China (Mathematical Statistics)
1986-1990: Ph.D. Purdue University, West Lafayette, Indiana, USA  (Statistics)

Research Interests:

Dr. Tan's research interests include clinical trial design and interim analysis, statistical methods to enhancing pivotal trial design using preclinical (xenograft) models that are predictive of clinical outcomes; statistical methods in molecular genetics and molecular pharmacology and in cancer drug development; Clinical trials designs with group sequential methods; Analysis of longitudinal data with continuous or ordinal or discrete outcome including mixed-effects models; Model adequacy checking; Methods to evaluate accuracy of diagnostic tests and biomarkers and cancer epidemiology; Bayesian hierarchical modeling and applied Bayesian methods.


Grant Support:

CURRENT

P30 CA 134274-01 (Cullen)
Period: 8/1/2008-7/30/2009
University of Maryland Cancer Center Support Grant
The goal of this grant is to provide infrastructure support to the University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Role: Director of Biostatistics Shared Service

R01 CA106767 (Tan)
Period: 4/1/04-3/31/2009
Design & Analysis of Preclinical Combination Studies
This grant is to develop innovative methods to optimally design and efficiently analyze pre-clinical drug combination therapies in cancer by integrating concepts in modern statistical and number-theoretic methods and pharmacology.
Role: Principal Investigator

U24 CA115091 (Stass)
Period: 03/01/2006-2/28/2010
University of Maryland Biomarker Reference Laboratory
The goal of this project is to move biomarkers developed within the EDRN into the clinic as directed by EDRN.
Role: Co-Investigator Biostatistician

1PO1 AT002605-01A1 (Berman)
Period: 09/30/2005-08/31/2009
Arthritis and Traditional Chinese Medicine
The overall goal of this research is to find an optimally efficacious, safe, and tolerable dosage of HLXL extract as adjunctive treatment in patients with OA of the knee.
Role: Co-Investigator Biostatistician

1U19AT003266-01 (Berman)
Period: 09/30/2005-09/30/2009
Functional Bowel Disorders in Chinese Medicine
The goal of the study is to determine the effect of Chinese medicine irritable bowel disorders.
Role: Co-Investigator Biostatistician

R03CA128102 ( Zhenqiu Liu)
Period: 05/01/07-04/30/09
Statistical and Computational Methods for Systematically Mining the SNP and Gene Expression Databases
The goal of this grant is to developing efficient algorithms for clustering, molecular network construction, and biomarker discovery with integrated SNP and gene expression data.
Role: Co-Investigator Biostatistician

RO1 DK 083770 (Reece)
Period: 9/18/2008-7/31/2012
Mechanisms of Diabetic Embryopathy and Molecular Pathways
The goal of this project is to understand how hyperglycemia changes the molecular and biochemical events in the developing embryo, causing abnormalities in newborn infants. The results of the study will provide information that will serve as a basis for future development of therapeutic interventions to prevent maternal diabetes associated birth defects.
Role: Co-Investigator Biostatistician


Publications:

Book (Peer Reviewed)

Tan M, Tian G-L, Ng KW. Bayesian Missing Data Problems: EM, Data Augmentation and Non-iterative Computation. London: Chapman and Hall/CRC, 2008.

Book chapters (Peer Reviewed)

Tan M. Conditional Power in Clinical Trial Monitoring. In: Wiley Encyclopedia of Clinical Trials D'Agostino R, ed., Wiley-Interscience 2008.

Tan M. Describing Data, Variability and Over-Dispersion in Medical Research. In Advanced Medical Statistics, J.Q. Fang and Y. Lu, eds., New York, World Scientific Publishing Co., New Jersey, page 319-332, 2003.

Tan M and Fang HB. Advanced Statistical Methods for the Design and Analysis of Tumor Xenograft Experiments. In Cancer Models With Applications to Cancer Screening, Cancer Treatment and Risk Assessment, WY Tan and A Yakovlev, eds., New York, World Scientific publishing Co. page 501-520, 2008.

Selected Publications (Peer Reviewed)

Tan M. Improved estimators for the (G)MANOVA problem with application to Monte Carlo simulation. Journal of Multivariate Analysis 38:262-274, 1991.

Tan M, Gleser LJ. Minimax estimators for location vectors in elliptical distributions with unknown scale parameter and its application to variance reduction in simulation. Ann. of the Inst. of Statist. Math. 44:537-550, 1992.

Papay FA, Hanna E, Gupta M, Lavertu P, Wood B and Tan M. The role of squamous cell carcinoma antigen, ferritin, and carcinoembryonic antigen as serum markers for head and neck tumors. Surg. Forum, 44:618-620, 1993.

Suh JH, Dass KK, Pagliaccio L, Taylor ME, Saxton JP, Saffle P, Tan M, Mehta AC. Endobronchial radiation therapy with or without ND:YAD laser resection for managing malignant airway obstruction. Cancer 73:2583-2588, 1994.

Riek RP, Handschumacher MD, Sung SS, Tan M, Glynias M, Schluchter MD, Novotny J, Graham RM. Evolutionary conservation of both the hydrophilic and hydrophobic nature of transmembrane residues. Journal of Theoretical Biology 172:245-258, 1995.

Qu T, Tan M, Kutner MH. Random-effects models in latent class analysis for evaluating accuracy of diagnostic tests. Biometrics 52:797-810, 1996.

Tan M, Xiong X. Continuous and group sequential conditional probability ratio tests for Phase II clinical trials. Statistics in Medicine, 15:2037-2051, 1996.

Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD for the Diabetic Renal Disease Study. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. New England Journal of Medicine 335:1636-1642, 1996.

Tan M, Qu Y, Kutner MH. Diagnostics in regression models for correlated binary data. Communications in Statistics Series B, 26:539-558, 1997.

Tan M, Xiong X, Kutner MH. Clinical trials designs based on sequential conditional probability ratio tests and reverse stochastic curtailing. Biometrics 54:684-697, 1998.

Tan M, Qu Y and Rao JS. Robustness of latent variable models for correlated binary data. Biometrics, 55:258-263, 1999.

Tan M, Qu Y, Mascha E and Schubert A. A Bayesian hierarchical model for multi-level repeated ordinal data. Statistics in Medicine. 18:1983-1992, 1999.

Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WM, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally in children with relapsed solid tumors. Cancer Chemotherapy and Pharmacology, 43:454-460, 1999

Song P and Tan M. Marginal models for longitudinal proportional data. Biometrics, 56:145, 2000.

Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette C, Tan M, Friedman HS and Brent TP. Antitumor activity of temozolomide combined with irinotecan is partly independent of MGMT and mismatch repair phenotypes in xenograft models. Clinical Cancer Research. 6:4110-4118, 2000.

Marshall DR, Turner JT, Belz GT, Wingo S, Andreansky S, Sangster MY, Riberdy, JM, Liu T, Tan M and Doherty PC. Measuring the dispora for virus specific CD8+ T cells. Proc. of Natl Academy of Sci. 98(11):6313-6318, 2001.

Skapek SX, Lin SCJ, Jablonski M, McKeller R, Tan M, Hu NP, Lee EYP. Persistent expression of cyclin D1 disrupts normal hotoreceptor differentiation and retina development. Oncogene. 20(46):6742-51. 2001.

Tan M, Fang HB, Tian G and Houghton PJ. Small Sample Inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics, 58:612-620. 2002.

Qiu Z, Song P and Tan M. Bayesian hierarchical models for multi-level ordinal data using WinBUGS. Journal of Biopharmaceutical Statistics, 12:121-135, 2002.

Schwartzberg L, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, Douglas L, Tan M, Billups C, Mihalik R, Weir A, Tauer K, Shope S, and Houghton JA. Modulation of the Fas Signaling Pathway by Interferon-gamma in Therapy of Colon Cancer: Phase I Trial and Correlative Studies of Interferon-gamma, 5-Fluorouracil and Leucovorin. Clinical Cancer Research. 8:2488-2498. 2002.

Xiong X, Tan M and Boyett J. Sequential conditional probability ratio tests for normalized test statistics on information time. Biometrics, 59:624-631, 2003

Tan M, Fang HB, Tian G and Houghton PJ. Experimental design and sample size determination for joint action of compounds based on uniform measures. Statistics in Medicine, 22:2091-2100, 2003.

Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ and Stewart CF. A pilot study of protracted topotecan using pharmacokinetically guided dosing approach in children with solid tumors. Clinical Cancer Research, 9:633-640. 2003.

Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD. Quantitative analysis of breast cancer resistance protein (BCRP) and cellular resistance to flavopiridol in acute leukemia patients. Clinical Cancer Research, 9:3320-8, 2003.

Crews K, Liu L, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP and Daw NC. High-Dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 100:1724-1733, 2004.

Govokorva EA, Fang H, Tan M, Webster R. NA Inhibitory-­Rimantadine Combinations Exert Additive and Synergistic Anti-influenza Effects in MDCK Cells. Antimicrobial Agents and Chemotherapy. 48:4855-4863. 2004.

Costello, LC, Feng P, Milon B, Tan M, Franklin RB. The role of zinc in the pathogenesis and treatment of prostate cancer: Critical Issues to Resolve. Prostate Cancer & Prostate Diseases. 7:111-117, 2004.

Tan M, Fang H, Tian GL and Houghton PJ. Repeated-measures models with constrained parameters for incomplete data in tumor xenograft experiments. Statistics in Medicine. 24:109-119, 2005.

Bauer K, Karp JE, Garimella TS, Wu S, Tan M, and Ross D. A Phase I and pharmacologic study of idarubicin, cytarabine, etoposide and PSC-833 in patients with refractory leukemia. Leukemia Research. 29:263-271, 2005.

Tan M, Tian G, and Ng K. Hierarchical Bayesian models for repeated binary data using the IBF sampler. Computational Statistics and Data Analysis. 50/5, 1272-1286. 2005.

Fang HB, Tian GL, Xiong X and Tan M. A restricted multivariate random-effects model with applications to assessing radiation therapy for brain tumors. Statistics in Medicine. 25:1948-1959, 2006

Rodriguez-Galindo, C., Crews, K.R., Stewart, C.F., Furman, W., Panetta, J.C., Daw, N.C., Cain, A., Tan, M., Houghton, P.H. and Santana, V.M. (2006) Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors, Cancer Chemother Pharmacol, 57, 15-24.

Tan M, Tian G-L, Fang H-B. A fast EM algorithm for quadratic optimization subject to convex constraints. Statistica Sinica 17: 945-964, 2007.

Liu Z, Lin S, Tan M. Genome-Wide Tagging SNPs with Entropy-Based Monte Carlo Method. J Computational Biology 13 (9): 1606-14, 2006

Xiong X, Tan M and Boyett J. A sequential procedure for monitoring clinical trials against historical controls. Statistics in Medicine, 26:1497â?"1511. 2007.

Liu Z, Jiang F, Tian GL, Wang S, Sato F, Meltzer SJ, Tan M. Sparse Logistic Regression with Lp Penalty for Biomarker Identification. Statistical Applications in Genetics and Molecular Biology 6 (1): Article 6, 2007.

Khanna N, Mishra SI, Tian GL, Tan M, Arnold S, Lee C, Ramachandran S, Bell L, Baquet C and Lorincz A. Human papillomavirus detection in self-collected vaginal specimens and matched clinician-collected cervical specimens. International Journal of Gynecological Cancer 17, 615-622. 2007.

Tkaczuk KHR, Goloubeva O, Tait NS, Feldman F, Tan M, Lum Z-P, Lesko SA, Van Echo DA, Ts'o P. The Significance of Circulating Epithelial Cells in Breast Cancer Patients by a Novel Negative Selection Method. Breast Cancer Research and Treatment (ePub) (2008).

Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ. Elevated expression of GST-Ï? and p53 confer poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone - an analysis of RTOG trials 9003 and 9501. Clinical Cancer Research 14(18): 5877-83, 2008.

Liu Z, Gartenhaus R, Tan M, Jiang F, Jiao X. Gene and pathway identification with Lp penalized Bayesian logistic regression. BMC Bioinformatics 9 (1): 412, 2008.

Liu Z and Tan M. ROC based utility function maximization for feature selection and classification with application to high dimensional gene expression data. Biometrics. 64:1155-1161, 2008.

Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA, Ross DD. Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias. Clin Cancer Res 15: 1698-1707, 2009.

Liu Z, Tan M and Jiang F. Regularized F-measure Maximization for Classification and feature selection. J. Biomedicine and Biotechnology. 6 (in press). 2009.
Liu Z, Chen X, Gartenhaus RB, Howell CD, Tan M. Survival Prediction and Gene Identification with Penalized Global AUC Maximization. Journal of Computational Biology (accepted), 2009.

Rapoport A, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, Janofsky S, Yager K, Veloso E, Zheng Z, Milliron T, Westphal S, Cotte J, Huynh H, Cannon A, Yanovich S, Akpek G, Tan M, Virts K, Ruehle K, Harris C, Philip S, Vonderheide R, Levine BL, June CH. Rapid Immune Recovery and GVHD-like Engraftment Syndrome Following Adoptive Transfer of Costimulated Autologous T Cells. Clin Cancer Res (accepted), 2009.